Ocugen Inc (OCGN)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.82-6.63%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · OCGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 323.1% |
| Our one-year growth estimate | diamond | 44.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 278.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is on a run of consecutive earnings misses and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
OCGN — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Ocugen, Inc (the “Company”) issued a press release announcing certain financial results for the quarter ended June 30, 2026. The Company has scheduled a conference call and webcast for 8:30 a.m. Eastern Time on August 6, 2026, to discuss these financial results and business updates. The Company will use presentation materials in connection with the conference call and webcast, which presentation materials will be posted on the…
Why it matters: This trial tests OCU410ST in Stargardt disease, which has no approved therapy. Ocugen completed dosing for all 63 patients.
Watch forTop-line results show the treatment group has less growth in lesion size than the control group at the planned time point.
Also watch forTop-line results show no clear reduction in lesion growth versus the control group, or the readout is delayed beyond 2Q 2027.
Why it matters: Ocugen is loss-making and relies on cash to fund its trials. The August financing was said to extend its runway into 2028.
Worry ifA quarterly filing shows cash and restricted cash at or above $100.4 million, the June 2026 level. It shows no new debt or share sale.
Less concerning ifA filing shows cash below $100.4 million, along with new debt or share sales. Or management no longer says cash will last through 2028.
Why it matters: The results test whether OCU400 helps people with many forms of RP. The company tied its rolling BLA plan to this readout.
Watch forTop-line data meet the primary endpoint. By Week 52, more treated patients than controls improved by at least 2 LDNA light levels.
Also watch forTop-line data miss the primary endpoint, or treated patients do not improve more than controls.
Why it matters: The October license turns the earlier term sheet into a signed deal. Its payments and royalties could show whether the partnership brings in cash.
Supportive ifOcugen reports an upfront or milestone payment. Or it reports MENA sales that earn the agreed 22% royalty.
Worry ifOcugen reports no payment or royalty revenue. It also says the license has ended or its key terms have changed.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$248 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $682 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,167 loss on $10,000 · 71.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The Phase 3 trial tests OCU410 for geographic atrophy. The company said it was on track to start in 3Q 2026.
Watch forThe company confirms its Phase 3 trial has started. It reports enrollment toward its planned total of about 237 patients.
Also watch forThe company reports that the trial has not started, or that the planned patient count or start timing has changed.